Results 131 to 140 of about 19,199 (236)

Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors. [PDF]

Curr Issues Mol Biol
Kuznetsova AA, Makhin AP, Bulygin AA, Andrianova AA, Miturich VS, Zagitova RI, Shmygarev VI, Fadeeva AA, Yatskin ON, Belozerova OA, Smirnov IV, Yampolsky IV, Kaskova ZM, Kuznetsov NA.   +13 more
europepmc   +1 more source

Role of Structural Modifications in Peptidomimetic Compounds as Potential Antimicrobial Agents against <i>Staphylococcus aureus</i> and <i>Streptococcus pyogenes</i>: Balancing Bioavailability, Safety, and Antimicrobial Activity. [PDF]

ACS Omega
Dzierżyńska M, Sawicka J, Łada K, Gajewicz-Skretna A, Deptuła M, Chernobrovkin A, Pogorzelska A, Grubb A, Zubarev RA, Pikuła M, Kasprzykowski F, Rodziewicz-Motowidło S.   +11 more
europepmc   +1 more source

Bacterial resistance and susceptibility to antimicrobial peptides and peptidomimetics [PDF]

, 2017
Citterio, Linda
core  

Novel macrocyclic peptidomimetics targeting the insulin-regulated aminopeptidase (IRAP): design, synthesis and evaluation. [PDF]

RSC Med Chem
Olaniran Håkansson E, Balestri LJI, Puthiyaparambath S, Moes S, Henschel H, Sköld C, Hallberg M, Larhed M, Skillinghaug B, Odell LR.   +9 more
europepmc   +1 more source

A Polyproline Type II Peptidomimetic Disrupts a Grb2 SH3C Domain Protein-Protein Interaction Implicated in Breast Cancer. [PDF]

Chembiochem
Luccarelli J, Simister PC, Hamilton AD, Feller SM, Thompson S.   +4 more
europepmc   +1 more source

Machine Learning-Guided Repositioning of a SARS-CoV-2-Targeting Molecular Series as Cruzain Inhibitors. [PDF]

ChemMedChem
Lameiro RF, Barbosa LF, Cardoso ER, Ho BS, Martins FCP, de Melo BC, Rosini F, Shamim A, Souza PM, de Souza WF, Montanari CA.   +10 more
europepmc   +1 more source

Toward the First Nonpeptidic Molecular Tong Inhibitor of Wild-Type and Mutated HIV-1 Protease Dimerization [PDF]

, 2010
Bannwarth L., Dufau L., Ongeri S., Piarulli U., Reboud-Ravaux M., Sicsic S., Soulier J.-L., Vidu A.   +7 more
core   +1 more source

A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models. [PDF]

PLoS Pathog
Ye Z, Dai W, Zhang S, Xiang Y, Wang J, Zhang Y, Cao W, Neyts J, Li Z, Feng F, Xiao G, Liu H, Cao J, Zhang LK.   +13 more
europepmc   +1 more source

In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria. [PDF]

PLoS One
Klose M, Weber L, Bachmann HS.
europepmc   +1 more source

A Three-Layer Transformation Strategy toward Functionalized Fused Hydantoins and Diketopiperazines. [PDF]

Org Lett
Giannakaki MA, Zingiridis M, Froudas KG, Neochoritis CG.   +3 more
europepmc   +1 more source